Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
3186studies shown
Showing 1,126-1,150 of 3,186
Active Not RecruitingNCT04951700

Aging and Disease Course: Contributions to Lifespan Neurobiology of Schizophrenia

This observational study is following people with psychosis to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information.

SchizophreniaOtherFrom 18 Years to 75 Years
Countries
United States
Sponsor
University of Texas Southwestern Medical Center
Condition
Schizophrenia
Active Not RecruitingNCT06360562

Reconnecting to Ourselves and Others in Virtual Meetings (ROOM)

This study is looking at care and outcomes for people with anxiety or psychosis. Taking part may give some people access to Resilience Training, but direct benefit is not guaranteed.

AnxietyOtherOver 14 Years
Countries
United States
Sponsor
Massachusetts General Hospital
Condition
Anxiety
RecruitingNCT05929352

Song-making In a Group (SING)

This study is looking at whether a digital support tool can help people with Schizophrenia. Participants take part in the therapy or support program and complete follow-up questionnaires or assessments.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Yale University
Condition
Schizophrenia
RecruitingNCT05440214

Targeting Emotion Dysregulation to Reduce Suicide in People With Psychosis

This study is looking at whether Dialectical Behavior Therapy Skills Training can help people with Psychosis or Suicide. Participants take part in Dialectical Behavior Therapy Skills Training and complete follow-up assessments.

SchizophreniaOtherOver 18 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
RecruitingNCT05617898

Determining the Role of Social Reward Learning in Social Anhedonia

This study is looking at whether Motivational Interviewing can help people with Psychosis. Participants take part in the program and complete follow-up questionnaires or assessments.

SchizophreniaOtherFrom 18 Years to 35 Years
Countries
United States
Sponsor
University of Alabama at Birmingham
Condition
Schizophrenia
RecruitingNCT06058702

Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans

This study is comparing Delta-9-THC Very Low Dose with placebo for people with Schizophrenia or Cannabis Use Disorder. Participants receive Delta-9-THC Very Low Dose or placebo and complete study visits and assessments.

SchizophreniaOtherFrom 21 Years to 60 Years
Countries
United States
Sponsor
Yale University
Condition
Schizophrenia
Active Not RecruitingNCT02407808

Cannabinoids, Learning, and Memory

This study is looking at care and outcomes for people with Cannabis or psychosis. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
United States
Sponsor
Yale University
Condition
Schizophrenia
RecruitingNCT04366518

Toward a Computationally-Informed, Personalized Treatment for Hallucinations

This study is comparing Rivastigmine Transdermal System with placebo for people with Hallucinations, Auditory or Psychosis. Participants receive Rivastigmine Transdermal System or placebo and complete study visits and assessments.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Yale University
Condition
Schizophrenia
RecruitingNCT06126224

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

This study is looking at care and outcomes for people with Psychosis Associated With Alzheimer's Disease. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.

SchizophreniaOtherFrom 55 Years to 90 Years
Countries
Belgium, Canada, Chile, China, Greece, Hungary, Mexico, Peru, Poland, South Korea, Switzerland, Turkey, United Kingdom, United States
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
RecruitingNCT05980949

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

This study is looking at care and outcomes for people with Psychosis Associated With Alzheimer's Disease. Taking part may give some people access to KarXT, but direct benefit is not guaranteed.

SchizophreniaOtherFrom 55 Years to 90 Years
Countries
Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czech Republic, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Mexico, Peru, Poland, Portugal, United States, Romania, Serbia, Slovakia, South Korea, Spain, Turkey, Ukraine, United Kingdom
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
RecruitingNCT07029581

Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

This study is looking at care and outcomes for people with Lewy Body Dementia Psychosis. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.

SchizophreniaOtherFrom 55 Years to 84 Years
Countries
Bulgaria, Czech Republic, France, Italy, Serbia, United States
Sponsor
ACADIA Pharmaceuticals Inc.
Condition
Schizophrenia
RecruitingNCT05511363

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

This study is looking at care and outcomes for people with Psychosis Associated With Alzheimer's Disease. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.

SchizophreniaOtherFrom 55 Years to 90 Years
Countries
Bulgaria, Croatia, Czech Republic, France, Germany, Italy, Serbia, Slovakia, Spain, United Kingdom, United States
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
RecruitingNCT06159673

ACP-204 in Adults With Alzheimer's Disease Psychosis

This observational study is following people with Alzheimer's Disease Psychosis to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information.

SchizophreniaOtherFrom 55 Years to 95 Years
Countries
Brazil, Bulgaria, Chile, Czech Republic, France, Italy, Mexico, Serbia, South Korea, Spain, Taiwan, United States
Sponsor
ACADIA Pharmaceuticals Inc.
Condition
Schizophrenia
Active Not RecruitingNCT05310838

Optimizing Engagement in Services for First-Episode Psychosis

This study is looking at whether Behavioral Activation for First Episode Psychosis can help people with Engagement or First Episode Psychosis. Participants receive Behavioral Activation for First Episode Psychosis or usual care and complete study visits and assessments.

SchizophreniaOtherFrom 15 Years to 35 Years
Countries
United States
Sponsor
California State University, San Bernardino
Condition
Schizophrenia
Enrolling By InvitationNCT06139874

Thrive Intervention in Schools

This study is looking at whether THRIVE can help people with Childhood Mental Disorder. Participants take part in THRIVE and complete follow-up assessments.

Mental healthOtherFrom 3 Years to 7 Years
Countries
United States
Sponsor
Washington University School of Medicine
Condition
Mental health
Active Not RecruitingNCT05554094

Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder

This study is looking at whether a digital support tool can help people with Ptsd, Stress Disorders, Traumatic, Stress Disorders, Post-Traumatic, or Trauma and Stressor Related Disorders. Participants receive a study treatment and complete follow-up visits and assessments.

Mental healthOtherFrom 21 Years to 64 Years
Countries
United States
Sponsor
Ohio State University
Condition
Mental health
Enrolling By InvitationNCT06194799

ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

This study is looking at care and outcomes for people with Alzheimer's Disease Psychosis. Taking part may give some people access to ACP-204, but direct benefit is not guaranteed.

SchizophreniaOtherFrom 55 Years to 95 Years
Countries
Brazil, Bulgaria, Chile, Czech Republic, France, Italy, Mexico, Serbia, South Korea, Spain, Taiwan, United States
Sponsor
ACADIA Pharmaceuticals Inc.
Condition
Schizophrenia
Active Not RecruitingNCT05967195

Trial to Increase FEP Attendance

This study is looking at whether Financial Incentive and Text-Messages can help people with First-Episode Psychosis. Participants take part in Financial Incentive and Text-Messages and complete follow-up assessments.

SchizophreniaOtherOver 18 Years
Countries
United States
Sponsor
University of Pennsylvania
Condition
Schizophrenia